RXDX Prometheus Biosciences Inc

2,341

$199.92

$0.18

(0.09%)

Today

Watchers	2,341
52-Wk Low	$25.65
52-Wk High	$199.98

Market Cap	$9.56B
Volume (M)	1.86M
52-Wk High	$199.98
52-Wk Low	$25.65

Fundamentals

Prometheus Biosciences, Inc. (NASDAQ:RXDX) Receives $153.36 Consensus Price Target from BrokeragesTicker Report • 6 months ago

Shares of Prometheus Biosciences, Inc. (NASDAQ:RXDX Get Rating) have earned a consensus rating of Hold from the eleven research firms that are covering the stock, Marketbeat Ratings reports. Seven research analysts have rated the stock with a hold recommendation and four have ...

Share to Feed

Brokerages Set Prometheus Biosciences, Inc. (NASDAQ:RXDX) Target Price at $153.36Zolmax • 6 months ago

Prometheus Biosciences, Inc. (NASDAQ:RXDX Get Rating) has been given an average recommendation of Hold by the eleven analysts that are currently covering the company, Marketbeat Ratings reports. Seven analysts have rated the stock with a hold recommendation and four have given a buy recommendation ...

Merck Completes Acquisition of Prometheus Biosciences, Inc.Business Wire • 6 months ago

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the completion of the Prometheus Biosciences, Inc. (Prometheus) (NASDAQ: RXDX) acquisition. Prometheus is now a wholly-owned subsidiary of Merck and the common stock of Prometheus will no longer be listed or...

Artia Global Partners LP Acquires Shares of 22,321 Prometheus Biosciences, Inc. (NASDAQ:RXDX)Ticker Report • 6 months ago

Artia Global Partners LP bought a new stake in Prometheus Biosciences, Inc. (NASDAQ:RXDX Get Rating) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities Exchange Commission. The fund bought 22,321 shares of the biopharmaceutical ...

Artia Global Partners LP Acquires Shares of 22,321 Prometheus Biosciences, Inc. (NASDAQ:RXDX)Zolmax • 6 months ago

Artia Global Partners LP bought a new stake in Prometheus Biosciences, Inc. (NASDAQ:RXDX Get Rating) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 22,321 shares of the biopharmaceutical companys stock...

Avidity Partners Management LP Invests $22.44 Million in Prometheus Biosciences, Inc. (NASDAQ:RXDX)Ticker Report • 6 months ago

Avidity Partners Management LP purchased a new position in shares of Prometheus Biosciences, Inc. (NASDAQ:RXDX Get Rating) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 204,000 shares of the ...

Point72 Asset Management L.P. Boosts Stock Position in Prometheus Biosciences, Inc. (NASDAQ:RXDX)Zolmax • 6 months ago

Point72 Asset Management L.P. boosted its holdings in Prometheus Biosciences, Inc. (NASDAQ:RXDX Get Rating) by 113.5% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,266,083 shares of the biopharmaceutical ...

Prometheus Biosciences Moves Up In Market Cap Rank, Passing Bath & Body WorksThe Online Investor • 6 months ago

In the latest look at stocks ordered by largest market capitalization, Russell 3000 component Prometheus Biosciences Inc (RXDX) was identified as having a larger market cap than the smaller end of the S&P 500, for example Bath & Body Works Inc (BBWI), according to The Online Investor. Click ...

Moran Wealth Management LLC Purchases New Holdings in Prometheus Biosciences, Inc. (NASDAQ:RXDX)Ticker Report • 6 months ago

Moran Wealth Management LLC acquired a new stake in Prometheus Biosciences, Inc. (NASDAQ:RXDX Get Rating) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 5,292 shares of the biopharmaceutical company&#...

Gyon Technologies Capital Management LP Invests $361,000 in Prometheus Biosciences, Inc. (NASDAQ:RXDX)Ticker Report • 6 months ago

Gyon Technologies Capital Management LP bought a new position in shares of Prometheus Biosciences, Inc. (NASDAQ:RXDX Get Rating) in the fourth quarter, according to its most recent filing with the Securities Exchange Commission. The institutional investor bought 3,285 shares of the ...